FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says.
Also in This 8-page Issue: NCI Seeks $6.17 Billion in “Bypass” Budget Request, But Faces Shortfall In Its Actual Budget.
NCI Names 15 to Director’s Consumer Liaison Group.
SAIC-Frederick Makes Awards To Proteomics Research Teams.
Latest State Cancer Statistics Released.
Smokers May Get Cessation Help From Medicare.
Funding Opportunities Listed.
Trending Stories
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- Robert Gallo named founding director of Microbial Oncology Program at TGH Cancer Institute
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch
- What are you reading in 2023?
- U.S. News rankings for cancer hospitals shift again with inclusion of Medicare Advantage data
Rankings now include a list of Best Regional Hospitals for Equitable Access - Infections are a major cause of death in patients treated with CAR T-cell therapy
Meta-analysis focused on causes of death, excluding relapse, recurrence
